Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM

Tagrisso (osimertinib) - AstraZeneca

BDTX-1535 - Black Diamond Therap

Matthew O'Connor1; Matthew Lucas2; Sherri Smith3; Anthony Trombino3; Sudharshan Eathiraj3; Elizabeth Buck1

Mar 14, 2023